2023
Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis
Sharma S, Li D, Levine L, Chaar A, McMillan C, Gaidos J, Proctor D, Al-Bawardy B. Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis. Crohn's & Colitis 360 2023, 5: otad032. PMID: 37323477, PMCID: PMC10263117, DOI: 10.1093/crocol/otad032.Peer-Reviewed Original ResearchAcute severe ulcerative colitisSevere ulcerative colitisClinical outcomesSigmoidoscopy groupHospital stayFlexible sigmoidoscopyUlcerative colitisIntravenous corticosteroid useRate of colectomyRisk of colectomyHours of admissionOpioid medication useShorter hospital stayCohort of patientsFavorable clinical outcomeLarge prospective studiesRelevant clinical outcomesColectomy rateCorticosteroid useSecondary outcomesMedication usePrimary outcomeProspective studyRetrospective studySigmoidoscopy
2022
IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE
Nawaz A, Glick L, Li D, Gaidos J, Proctor D, Al-Bawardy B. IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE. Inflammatory Bowel Diseases 2022, 28: s107-s108. DOI: 10.1093/ibd/izac015.174.Peer-Reviewed Original ResearchSteroid-free clinical remissionC-reactive proteinNon-therapeutic dosesInflammatory bowel diseaseNormal C-reactive proteinAnti-TNF antibodiesCombination therapyTherapeutic doseEndoscopic healingNTD groupAntibody formationUlcerative colitisClinical outcomesCrohn's diseaseNormal serum C-reactive proteinAnti-TNF combination therapyAnti-TNF drug levelsSerum C-reactive proteinEffect of thiopurinesImpact of thiopurinesAnti-TNF treatmentRetrospective cohort studyNormal TPMT activityUnpaired Student's t-testTerms of baselineImpact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
Nawaz A, Glick L, Chaar A, Li D, Gaidos J, Proctor D, Al-Bawardy B. Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease. Annals Of Gastroenterology 2022, 36: 39-44. PMID: 36593807, PMCID: PMC9756033, DOI: 10.20524/aog.2022.0766.Peer-Reviewed Original ResearchInflammatory bowel diseaseC-reactive proteinAnti-TNF combination therapySteroid-free clinical remissionCombination therapyThiopurine doseDose groupEndoscopic healingClinical remissionBowel diseaseUlcerative colitisCrohn's diseaseTherapeutic doseNormal serum C-reactive proteinAnti-tumor necrosis factorNormal C-reactive proteinSerum C-reactive proteinAnti-drug antibody formationAnti-TNF immunogenicityCohort of patientsLow-dose groupSignificant differencesSecondary outcomesPrimary outcomeClinical outcomes
2016
Timing of Last Preoperative Dose of Infliximab Does Not Increase Postoperative Complications in Inflammatory Bowel Disease Patients
Alsaleh A, Gaidos JK, Kang L, Kuemmerle JF. Timing of Last Preoperative Dose of Infliximab Does Not Increase Postoperative Complications in Inflammatory Bowel Disease Patients. Digestive Diseases And Sciences 2016, 61: 2602-2607. PMID: 27126205, PMCID: PMC4982818, DOI: 10.1007/s10620-016-4171-9.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal AbscessAdolescentAdultAnastomotic LeakChildColitis, UlcerativeCrohn DiseaseDigestive System Surgical ProceduresFemaleGastrointestinal AgentsHumansIleusInflammatory Bowel DiseasesInfliximabIntestinal ObstructionMaleMiddle AgedPostoperative ComplicationsPreoperative CareReoperationRetrospective StudiesRisk FactorsSurgical Wound InfectionTime FactorsVenous ThromboembolismYoung AdultConceptsLast preoperative dosePostoperative complicationsInflammatory bowel diseasePreoperative doseLast doseUlcerative colitisCrohn's diseaseInflammatory bowel disease patientsMethodsRetrospective chart reviewBowel disease patientsResultsNo significant associationIBD patientsPreoperative statusChart reviewPreoperative useBackgroundThe associationBowel diseaseSurgeon typeSurgery typeSteroid useDisease patientsInfliximabComplicationsPatientsDisease typeHow to Optimize Colon Cancer Surveillance in Inflammatory Bowel Disease Patients
Gaidos JK, Bickston SJ. How to Optimize Colon Cancer Surveillance in Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases 2016, 22: 1219-1230. PMID: 26926040, DOI: 10.1097/mib.0000000000000685.Peer-Reviewed Original ResearchConceptsInflammatory bowel disease patientsBowel disease patientsColonic Crohn's diseaseColorectal neoplasiaUlcerative colitisDisease patientsCurrent surveillance guidelinesDuration of diseasePrimary sclerosing cholangitisExtent of diseaseOverall high riskColon cancer surveillanceColonic IBDColorectal dysplasiaSclerosing cholangitisSurveillance colonoscopyConcomitant diagnosisCrohn's diseaseSporadic colon cancerChronic inflammationSociety guidelinesSurveillance guidelinesCancer surveillanceRisk factorsFamily history